Skip to content

A Clinical Comparison of Two Soft Toric Contact Lenses

A Clinical Comparison of Two Soft Toric Contact Lenses

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06758089
Enrollment
42
Registered
2025-01-03
Start date
2024-11-08
Completion date
2024-12-19
Last updated
2026-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Astigmatism

Brief summary

The aim of this study is to compare the short-term clinical performance of two toric contact lenses.

Detailed description

The aim of this study is to evaluate the short-term clinical performance of two toric contact lenses when compared to each other after 15 minutes of daily wear each.

Interventions

15 minutes of daily wear

15 minutes of daily wear

Sponsors

CooperVision International Limited (CVIL)
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. They are of legal age and capacity to volunteer. 2. They understand their rights as a research subject and are willing and able to sign a Statement of Informed Consent. 3. They are willing and able to follow the protocol. 4. They currently wear soft contact lenses, or have done so within the past two years. 5. They have ocular astigmatism in both eyes of between 0.75DC and 2.00DC. 6. They have a spherical component: plano to -7.00DS (based on ocular refraction). 7. They are expected to be able to be fitted with the study lenses within the power range available.

Exclusion criteria

1. They have an ocular disorder, which would normally contra-indicate contact lens wear. 2. They have a systemic disorder, which would normally contra-indicate contact lens wear. 3. They are using any topical medication such as eye drops or ointment. 4. They are aphakic. 5. They have had corneal refractive surgery. 6. They have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus. 7. They are pregnant or breastfeeding. 8. They have an eye or health condition including an immunosuppressive or infectious disease which would, in the opinion of the investigator, contraindicate contact lens wear or pose a risk to study personnel; or a history of anaphylaxis or severe allergic reaction. 9. They have taken part in any contact lens or care system clinical research within two weeks prior to starting this study.

Design outcomes

Primary

MeasureTime frameDescription
Subjective Overall ScoreAt the end of 15 minutes of daily wearThe primary outcome measure for this study is the subjective overall score on a scale of 0-100. (0 = Extremely poor. Unmanageable. Cannot use lenses. 100 = Excellent. Highly impressed with these lenses overall.)

Secondary

MeasureTime frameDescription
Subjective VisionAt the end of 15 minutes of daily wearThe secondary outcome measure for this study is the subjective vision on a scale of 0-100. (0 = Extremely poor. Intolerable. Lenses cannot be worn. 100 = Excellent. Unaware of any visual loss.)
Subjective ComfortAt the end of 15 minutes of daily wearThe secondary outcome measure for this study is the subjective comfort on a scale of 0-100. (0 = Extremely uncomfortable. Causes pain. Cannot be tolerated. 100 = Excellent. Cannot be felt.)

Countries

United Kingdom

Contacts

PRINCIPAL_INVESTIGATORCarole Maldonado-Codina, PhD, FBCLA

Eurolens Research

Participant flow

Pre-assignment details

Forty-two participants were screened. Two participants were not eligible due to screening failure. All the participants who were eligible in the study were included in the analysis. (n=40)

Baseline characteristics

Characteristic
Age, Continuous37.2 Years
STANDARD_DEVIATION 13.4
Sex: Female, Male
Female
26 Participants
Sex: Female, Male
Male
14 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 400 / 40
other
Total, other adverse events
0 / 400 / 40
serious
Total, serious adverse events
0 / 400 / 40

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026